NCT03413358

Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid

A Randomized, Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Sheng Bai Oral Liquid in Prevention and Treatment for The Decrease of Neutrophils After Chemotherapy in Patients With Non-Small-Cell Lung Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: BeiJing Yijiayi Medicine Techonoloy Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.

Detailed description

The Clinical trail is a multicenter, prospective, randomized controlled study. The planned sample size is 240 subjects. These subjects will be randomized (1:1) to treatment group (Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid) or control group ( Platinum-based two medicine (carboplatin / cisplatin) plus blank control). The study population includes the patients with non-small-cell lung cancer .

Conditions

• Non-small-Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Sheng Bai oral liquid	Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy. Subjects will be treated for 2 courses
DRUG	Platinum-based two medicine (carboplatin / cisplatin) .	Using Platinum-based two medicine (carboplatin / cisplatin)

Timeline

• Start date: 2018-01-15
• Primary completion: 2019-10-31
• Completion: 2019-10-31
• First posted: 2018-01-29
• Last updated: 2018-01-29

Locations

1 site across 1 country: China